logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10738041 B1

PDFFull Text
Date of Patent:
Aug. 11, 2020

Filed:

Oct. 21, 2016

Ferroportin inhibitors

Applicant:

Vifor (International) Ag, St. Gallen, CH;

Inventors:

Franz Dürrenberger, Dornach, CH;

Wilm Buhr, Constance, DE;

Susanna Burckhardt, Zürich, CH;

Michael Burgert, Friedrichshafen, DE;

Aris Kalogerakis, Winterthur, CH;

Stefan Reim, St. Gallen, CH;

Vania Manolova, Zollikon, CH;

Susan Boyce, Quickborn, DE;

Christopher John Yarnold, Didcot Oxon, GB;

Paula Pena, Witney, GB;

Jon Shepherd, Abingdon, GB;

Cristina Lecci, Abingdon, GB;

Richard Jarjes-Pike, Newbury, GB;

John Scott, Abingdon, GB;

Assignee:

Vifor (International) AG, St. Gallen, CH;

Attorneys:

Rankin, Hill & Clark LLP

Christopher Jan Korff

Primary Examiner:

Yevgeny Valenrod

Int. Cl.
CPC ...
C07D 413/14 (2006.01); A61K 31/427 (2006.01); A61K 31/437 (2006.01); A61K 31/444 (2006.01); A61K 31/501 (2006.01); A61K 31/506 (2006.01); A61K 31/55 (2006.01); C07D 417/12 (2006.01); C07D 471/04 (2006.01); C07D 401/14 (2006.01); A61K 31/426 (2006.01); A61K 31/435 (2006.01); A61K 31/497 (2006.01); A61K 45/06 (2006.01); C07D 277/56 (2006.01); C07D 403/14 (2006.01); C07D 413/04 (2006.01); C07D 487/04 (2006.01); A61K 31/4184 (2006.01); A61K 31/4355 (2006.01); A61K 31/4375 (2006.01); A61K 31/4439 (2006.01); A61K 31/4985 (2006.01); A61K 31/5377 (2006.01); C07D 417/14 (2006.01); A61K 31/4709 (2006.01); A61K 31/4725 (2006.01); A61P 7/06 (2006.01); A61P 25/28 (2006.01); A61P 25/16 (2006.01); A61P 3/12 (2006.01); A61K 31/16 (2006.01); A61K 31/4422 (2006.01); A61K 36/9066 (2006.01);
U.S. Cl.
CPC ...
C07D 413/14 (2013.01); A61K 31/4184 (2013.01); A61K 31/426 (2013.01); A61K 31/427 (2013.01); A61K 31/435 (2013.01); A61K 31/437 (2013.01); A61K 31/4355 (2013.01); A61K 31/4375 (2013.01); A61K 31/444 (2013.01); A61K 31/4439 (2013.01); A61K 31/4709 (2013.01); A61K 31/4725 (2013.01); A61K 31/497 (2013.01); A61K 31/4985 (2013.01); A61K 31/501 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/55 (2013.01); A61K 45/06 (2013.01); A61P 3/12 (2018.01); A61P 7/06 (2018.01); A61P 25/16 (2018.01); A61P 25/28 (2018.01); C07D 277/56 (2013.01); C07D 401/14 (2013.01); C07D 403/14 (2013.01); C07D 413/04 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); A61K 31/16 (2013.01); A61K 31/4422 (2013.01); A61K 36/9066 (2013.01); A61K 2300/00 (2013.01); Y02A 50/411 (2018.01);
Abstract

The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.

Find Patent Forward Citations

Loading…